ApiFix’s Post

One year ago I was a P4 student completing an ambulatory care rotation at LMH with Emily Prohaska, PharmD, BCACP, FAPhA. This rotation (and Emily because she's the best!) helped me realize my passion and interest in osteoporosis since it is so common but largely undiagnosed and undertreated. During my current PGY1 residency at Creighton University School of Pharmacy, I completed my first Grand Rounds presentation overviewing osteoporosis. I recently wrote a newsletter for PharMerica discussing diagnosis and treatment of osteoporosis, focusing on non-oral treatment options. My article link is attached below for anyone interested in reading more about this topic!

Learn how our client set their Phase II clinical trial up for success by gathering early insights from oncologists, nurses & patients through the Impetus InSite Platform®. Download our customer story to see how we're transforming clinical trials! https://hubs.la/Q02m_Q-h0 #ClinicalTrials #Innovation #PatientCentricTrials #PatientEngagement #OncologyInnovation

🚀 Exciting News in Medical Innovation! BiVACOR Inc® receives $13 Million to Support Clinical Trials for the Company’s Total Artificial Heart 🏥💡 In a significant stride towards advancing cardiac care, BiVACOR Inc® has secured $13 million in funding will be used to bolster clinical trials for its ground-breaking Total Artificial Heart technology. This investment underscores the immense potential of BiVACOR Inc®'s innovative approach to cardiac health. “There is a huge gap between available treatment options and the number of patients with severe heart failure. Initiating human clinical work for the BiVACOR Inc #TAH is the first step to address critical patient needs from this non-curative disease,” - Daniel Timms, BiVACOR Inc Founder and Chief Technology Officer. This substantial funding infusion will not only accelerate the clinical trial process but also pave the way for broader accessibility to this life-saving technology. It is a testament to the confidence investors have in BiVACOR Inc®'s vision and the transformative impact it can have on cardiac medicine. As we celebrate this milestone, let's acknowledge the dedication and ingenuity of the BiVACOR Inc® team in driving innovation in cardiovascular health. Together, we move closer to a future where advanced medical technologies offer hope and healing to those in need.   https://lnkd.in/e3Veeb7c #MedicalInnovation #CardiacHealth #BiVACOR #ArtificialHeart #ClinicalTrials #HealthcareTechnology #MedTech #HeartFailure #MedicalDevice

Learn how our client set their Phase II clinical trial up for success by gathering early insights from oncologists, nurses & patients through the Impetus InSite Platform®. Download our customer story to see how we're transforming clinical trials! https://hubs.la/Q02m_N-h0 #ClinicalTrials #Innovation #PatientCentricTrials #PatientEngagement #OncologyInnovation

This past spring, six patient representatives from the NF1 community met virtually with the FDA to share their experiences with cutaneous neurofibromas (cNFs). During the session, patient advocates emphasized the need for the medical community to understand that these are not merely cosmetic concerns. The FDA staff – who are experts in their fields and among the best science has to offer – listened attentively to the shared experiences of these brave NF patients, experiences that are not captured in medical charts or scans. This meeting, coordinated by the Children's Tumor Foundation, is a crucial step in ensuring the voices of those living with NF1 are heard and considered in future FDA evaluations. Read the summary report here --> https://lnkd.in/g2eaB6xV #endnf #makenfvisible #patientengagement #patientadvocacy #fdalisteningsession

Exciting News! Mainstay Medical proudly announces the publication of clinical results comparing older and younger patients in a pooled analysis of three studies evaluating the safety and efficacy of ReActiv8 Restorative Neurostimulation. No significant differences were found, highlighting the therapy's consistent effectiveness across age groups. Jason Hannon, CEO of Mainstay Medical, stated: “High quality clinical evidence sets us apart in this industry. We study, learn, and demonstrate outcomes in patient populations before we suggest ReActiv8 is beneficial to a particular group of patients. This is how we partner with clinicians to deliver the best possible, and most durable, treatments for their patients. With these exciting results demonstrating the value of ReActiv8 across all studied age groups, we can now confidently support identification of older patients who are likely to benefit from the therapy. We look forward to continuing to partner with physicians to help chronic low back pain patients of all ages, and to growing the global body of peer-reviewed evidence supporting the ability of ReActiv8 to provide positive long-term outcomes.” View press release here → https://lnkd.in/es9U-A2p. #mainstaymedical #reactiv8 #multifidusdysfunction #chroniclowbackpain #restorativetherapy #thinkrestorative #restorativerevolution #lowbackpain #clbp #helpingpatients #patientfocus #puttingpatientsfirst Dr. Ardeshir Ardeshiri | Marco Amann | Simon Thomson | Christopher Gilligan, M.D.

🫀🏥Promising #clinicaldata and positive momentum for the team at atHeart Medical toward their novel, reSept, atrial septal defect (ASD) #occluder. The reSept offers a unique and 1st of its kind #bioresorbable frame for #transcatheter based septal closure treatment offering improved #biocompatibility versus traditional metallic frames. The promising long & short-term reSept clinical findings will be presenting at the upcoming CSI Frankfurt including their 10 year ASCENT study outcomes alongside two year pivotal data across the US, Canada, and the EU as well as a one-month efficacy study for patients with iatrogenic ASDs due to #mitralvalve intervention. “Around 100 patients have been implanted with reSept to date. While hospitals continue to enroll patients as part of ASCENT ASD in several countries, we are excited that these positive outcomes showcase the potential for reSept to soon be the new standard of care.” Laurent Grandidier, atHeart Medical CEO #structuralheart #clinicalstudy #cardiacimplants The Mullings Group MassDevice

It’s Holly Scott’s #medtech roundup. It’s tradeshow season. Why go? Holly mentioned some upcoming conferences and it struck me - tradeshow and conference season is upon us. How do you choose which ones to attend? Time and expense are big factors for me. How about you? In the US and for my part of #medtech, there are 3: Vision Expo West (Vegas), Vision By Design (DFW) and American Academy Of Optometry (Indy). I’m definitely going to Vegas. Though I have a “2 night fuse” for Vegas, the show has interesting exhibits and generally good biannual business meetings with key customers. There’s also a ton of folks at the show to connect with. If you’re going to VEW, hit me up. The other two are a toss up. The DFW show has gone downhill since COVID…but there’s a chance more folks will attend this year. The Indy show is primarily academic and scientific, but my big company has a whole team dedicated to that. Plus, scheduling is tough as we begin our fiscal year. How do you choose? ————— Social media brings the world to your phone. Use it for your professional development. I follow folks like Holly Scott, Kevin Berchelmann, Joe Mullings, Erich Mattei and Matthew Ray Scott to broaden my thinking and keep me up to speed on the market. Who do you follow? How do they help you? #leadership #changinglives #dothething